• Baxter International Inc. (NYSE:BAX) maintains an "Outperform" rating from Evercore ISI with a revised price target of $23, indicating a potential upside.
• The company's stock price shows a slight increase, trading at $20.59, amidst market fluctuations.
• Baxter's upcoming presentation at the J.P. Morgan 2026 Healthcare Conference is highly anticipated for potential impacts on its stock performance.

Baxter International Inc. (NYSE:BAX) is a prominent player in the healthcare industry, known for its innovative medical products and services. The company is set to present at the J.P. Morgan 2026 Healthcare Conference, a key event that gathers influential figures in the healthcare sector. This platform allows Baxter to highlight its strategies and innovations, potentially impacting its stock performance by revealing new insights into its future plans.

On January 5, 2026, Evercore ISI maintained its "Outperform" rating for BAX, indicating confidence in the company's performance. Despite this positive outlook, Evercore ISI adjusted Baxter's price target from $24 to $23. At the time, the stock price was $19.84, suggesting a potential upside of approximately 14.86% from the target, as noted by Vijay Kumar from Evercore ISI.

Currently, BAX is trading at $20.59, reflecting a slight increase of 0.91% or $0.19. The stock has experienced fluctuations, trading as low as $20.08 and as high as $20.62 today. Over the past year, BAX has seen a high of $37.74 and a low of $17.40, indicating significant volatility in its stock price.

Baxter's market capitalization stands at approximately $10.58 billion, highlighting its substantial presence in the healthcare market. The trading volume for the day is 9,514,299 shares, showing active investor interest. As Baxter prepares for its presentation at the J.P. Morgan Healthcare Conference, stakeholders will be keenly observing for any announcements that could influence its stock trajectory.